Form 4: ImmunityBio Executive Chairman Patrick Soon-Shiong Reports Acquisition of Stock Options and Restricted Stock Units

Patrick Soon-Shiong, Executive Chairman of ImmunityBio, reports the acquisition of stock options and restricted stock units in a recent SEC filing.

Summary

• Patrick Soon-Shiong, Executive Chairman, Global Chief Scientific and Medical Officer, and a 10% owner of ImmunityBio, Inc. (IBRX), filed a Form 4 with the SEC.
• The filing reports transactions occurring on February 10, 2025.
• Soon-Shiong acquired 822,368 Restricted Stock Units (RSUs) and 2,812,500 stock options.
• The RSUs and stock options vest in equal annual installments over three years, starting February 10, 2025, contingent upon continued service.
• The exercise price of the stock options is $3.39.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options and RSUs by a key executive suggests confidence in the company's future, but it's a routine filing and doesn't contain groundbreaking news.

Positives

• The acquisition of RSUs and stock options by a key executive like Patrick Soon-Shiong could signal confidence in the company's future performance.
• The vesting schedule incentivizes continued service and commitment from Soon-Shiong.

Future Outlook

The vesting schedule of the RSUs and stock options suggests a focus on long-term value creation and retention of key personnel.

Industry Context

Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders and incentivize long-term growth. This filing reflects a standard practice in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation in the biotechnology industry, often used to incentivize performance and align executive interests with shareholder value.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options and restricted stock units as part of their executive compensation packages.
• The vesting schedules described in this filing are typical, with vesting occurring over a period of several years to encourage long-term commitment.

Stakeholder Impact

• The acquisition of equity by a key executive can positively influence shareholder confidence.
• The vesting schedule incentivizes the executive to remain with the company, benefiting employees and other stakeholders.

Key Dates

Keywords

ImmunityBio, IBRX, Patrick Soon-Shiong, Form 4, SEC Filing, Restricted Stock Units, Stock Options, Beneficial Ownership, Executive Compensation